These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2715804)

  • 1. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties.
    Delmer A; Marie JP; Thevenin D; Cadiou M; Viguié F; Zittoun R
    J Clin Oncol; 1989 Jun; 7(6):738-46. PubMed ID: 2715804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.
    Basara N; Radosević-Radojković N; Colović M; Bosković D; Rolović Z
    Eur J Haematol; 1995 Aug; 55(2):83-7. PubMed ID: 7628594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of clonogenic assay for induction and duration of complete remission in acute myelogenous leukemia.
    Marie JP; Zittoun R; Delmer A; Thevenin D; Suberville AM
    Leukemia; 1987 Feb; 1(2):121-6. PubMed ID: 3478535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative heat sensitivity of murine and human hemopoietic progenitors and clonogenic leukemia cells.
    Gidáli J; Fehér I; Kovács P
    Stem Cells; 1994 Sep; 12(5):533-8. PubMed ID: 7804126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of drug sensitivity in vitro with clinical responses in childhood acute myeloid leukemia.
    Dow LW; Dahl GV; Kalwinsky DK; Mirro J; Nash MB; Roberson PK
    Blood; 1986 Aug; 68(2):400-5. PubMed ID: 3460647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
    De Witte T; Muus P; Haanen C; Van der Lely N; Koekman E; Van der Locht A; Blankenborg G; Wessels J
    Behring Inst Mitt; 1988 Aug; (83):301-7. PubMed ID: 3071344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced chemosensitivity in acute myeloid leukemia by hematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay.
    te Boekhorst PA; Löwenberg B; Sonneveld P
    Leukemia; 1993 Oct; 7(10):1637-44. PubMed ID: 7692194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.
    Ysebaert L; Chicanne G; Demur C; De Toni F; Prade-Houdellier N; Ruidavets JB; Mansat-De Mas V; Rigal-Huguet F; Laurent G; Payrastre B; Manenti S; Racaud-Sultan C
    Leukemia; 2006 Jul; 20(7):1211-6. PubMed ID: 16688229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
    te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
    Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
    Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
    J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
    Castagnola C; Nozza A; Corso A; Bernasconi C
    Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
    te Boekhorst PA; Löwenberg B; Sonneveld P
    Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
    Lemoli RM; Gulati SC; Strife A; Lambek C; Perez A; Clarkson BD
    Leukemia; 1991 May; 5(5):386-91. PubMed ID: 1709711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
    Grant S; Bhalla K; Arlin Z; Howe CW
    Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of residual disease in acute myeloid leukemia using light density gradients and culture assay.
    Ciaudo M; Marie JP; Ifrah N; Thevenin D; Zittoun R
    Pathol Biol (Paris); 1988 Jan; 36(1):67-71. PubMed ID: 3283676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.